The metabolic profiles and pharmacokinetics of pemafibrate, a novel selective peroxisome proliferator activated receptor‐alpha modulator currently launched as an antidyslipidemic drug, were investigated in vitro using hepatocytes from rats, monkeys and humans and in vivo in rats and monkeys. Hepa…